Technology growth

Exosome Drug Delivery Technology Growth Opportunities Market Research 2022 – Increasing R&D Collaborations and Emerging Therapeutic Pipelines –

DUBLIN–(BUSINESS WIRE)–The “Technology Growth Opportunities for Exosome-Mediated Drug Delivery” report has been added to from offer.

This research provides an overview of emerging modalities provided by exosomes at preclinical or clinical stages, highlighting technology roadmaps, market trends, and latest research findings.

The study examines the different routes of administration to inject these fractions into the human body and the notable R&D collaborations and licensing agreements between pharmaceutical companies, biotechnology companies and academic partners for the development of commercial products after transfer. of technology.

Codiak BioSciences, Capricor Therapeutics and Evox Therapeutics are among key companies with numerous pipeline candidates, significant investments and strategic R&D partnerships in the area of ​​drug delivery via exosomes for disease indications such as cancer, COVID-19, rare diseases and neurological diseases. troubles. This study completes the analysis with growth opportunities for the clinical translation of exosome nanocarriers.

Drug delivery via exosomes is a promising alternative to conventional drug delivery methods, making rapid progress in the biopharmaceutical industry due to the safety and efficacy advantages that exosomes offer in as nanocarriers compared to synthetic nanoparticles. The widely explored concepts of nanomedicine, nucleic acid therapeutics, and cell-free vaccines have bolstered the inclusion of exosomes in the delivery of new drug modalities.

Non-immunogenicity, biocompatibility and stability are key characteristics that make exosomes attractive as carriers in the biopharmaceutical sector. As such, microRNAs, small interfering RNAs, the CRISPR-Cas9 system, viral vectors, antisense oligonucleotides, messenger RNA (mRNA) vaccines, heteroduplexes, surface antigens and protein antibodies have emerged as cargo modalities, packaged endogenously or exogenously in natural or artificial products. exosomes.

Exosomes alleviate the problems of stability, low bioavailability, targeting, reduced gene expression, membrane uptake, and cellular degradation that other nanocarriers face in drug delivery modalities. There is a growing body of research and clinical evidence to support the immense value of exosomes in delivering mRNA vaccines, gene editing tools, gene therapy, and disease-related small proteins to treat life-threatening conditions.

Exosomes are also used to develop mRNA and other advanced therapeutic formulations that can be delivered by more patient-compliant routes, such as oral and intranasal. These extracellular vesicles are designed on the surface to maximize payload efficiency and targeted delivery.

Increasing R&D on delivery specificity, cellular uptake and exosome signaling effect is accelerating the development of new exosome-mediated drug delivery technologies for better patient outcomes. The United States has become the hub of the exosome drug delivery industry, with many private and academic institutions conducting research and adopting technologies.

Europe is also seeing a considerable amount of R&D activity as intensive collaborations accelerate the development of exosomes as nanocarriers. The scalability of exosome production remains a problem, but biotech companies are tackling it by building new manufacturing platforms and searching for new sources of extracellular vesicles. These engines have opened up new growth opportunities to access non-drug targets associated with rare and fatal diseases.

Main topics covered:

1 Strategic imperatives

  • Why is it increasingly difficult to grow taller? Factors exerting pressure on growth

  • The strategic imperative

  • The Impact of Top 3 Strategic Imperatives on the Exosome Drug Delivery Industry

  • Growth opportunities fuel the growth pipeline engine

2 Analysis of growth opportunities

  • Scope of analysis

  • Segmentation

  • Research Methodology

  • Exosomes are electric vehicles with targeted delivery potential

  • Growth engines

  • Growth constraints

  • Increasing R&D Collaborations and Emerging Therapeutic Pipelines with Exosome-Based Delivery

3 Technology Overview: Exosome Drug Delivery

  • Exosomes are the most promising nanocarriers

  • Innate stability, low immunogenicity and biocompatibility lead to the use of exosomes as nanocarriers

  • MEs and engineered exosomes are gaining popularity

  • Growing adoption of chemical conjugation methods to encapsulate biomolecules into exosomes

  • Intranasal and oral administration emerging as patient-compliant routes

  • Surface engineering of exosomes is important for targeted delivery to organs

4 Innovation Landscape: Emerging Modalities Leveraging Exosomes

  • Emerging therapeutic modalities using exosomes

  • Endogenously loaded exosomes for mRNA vaccine delivery are promising alternatives to LNP vehicles

  • Exosome-based mRNA vaccines for infectious diseases

  • Promising nonviral delivery carriers for gene therapy and editing

  • R&D on exosomes delivering CRISPR-Cas9 for gene editing

  • Prevalence of exosome delivery of RNAi therapies using endogenous loading

  • Exosome-mediated delivery of RNAi molecules finds wide adoption

  • Endogenous loading of exosomes with small proteins for inflammation pathways

  • R&D partnerships focused on the delivery of small proteins associated with inflammation

  • Exogenous loading of exosomes enhances targeted delivery

  • Codiak BioSciences delivers most cargo by exogenous loading

  • Intranasal and oral routes of administration are ready to develop

  • Nasally delivered exosomes show promise for vaccine delivery and CNS targeting

5 Market Analysis, Funding Landscape, Mergers and Acquisitions

  • Increase R&D collaborations and licensing agreements between exosome therapeutic/distributor companies and major pharmaceutical participants

  • Recent R&D collaborations indicate a growing body of work in CNS targeting and gene therapy delivery

  • Delivery of COVID-19 mRNA vaccine attracted major funding from venture capital and federal government

  • Emerging Trends in Exosome Drug Delivery

6 Universe of growth opportunities

  • Growth Opportunity 1: Mass Production of Artificial Exosomes Mimicking Natural Exosomes for Drug Delivery

  • Growth Opportunity 2: Autologous Exosomes in Personalized Cancer Immunotherapy

  • Growth Opportunity 3: Collaborations Between Exosome Manufacturing Services and Pharmaceutical Companies

7 Appendix

  • The number of visitors to the ExoCarta database has increased over the past decade

  • Surface display of fusion proteins attach exogenous cargo

  • Notable patents

For more information about this report visit